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Anaplastic lymphoma receptor tyrosine kinase (ALK) gene rearrangements occur in a subgroup of non-small cell lung carcinomas
(NSCLCs). e identi�cation of these rearrangements is important for guiding treatment decisions. e aim of our study was
to screen ALK gene fusions in NSCLCs and to compare the results detected by targeted resequencing with results detected by
commonly usedmethods, including �uorescence in situ hybridization (FISH), immunohistochemistry (IHC), and real-time reverse
transcription-PCR (RT-PCR). Furthermore, we aimed to ascertain the potential of targeted resequencing in detection of ALK-
rearranged lung carcinomas.We assessedALK fusion status for 95 formalin-�xed para�n-embedded tumor tissue specimens from
87 patients with NSCLC by FISH and real-time RT-PCR, for 57 specimens from 56 patients by targeted resequencing, and for 14
specimens from 14 patients by IHC. All methods were performed successfully on formalin-�xed para�n-embedded tumor tissue
material. We detected ALK fusion in 5.7% (5 out of 87) of patients examined. e results obtained from resequencing correlated
signi�cantly with those from FISH, real-time RT-PCR, and IHC. Targeted resequencing proved to be a promising method for ALK
gene fusion detection in NSCLC. Means to reduce the material and turnaround time required for analysis are, however, needed.
1. Introduction
Chromosomal rearrangements involving anaplastic lym-
phoma receptor tyrosine kinase (ALK), a member of receptor
tyrosine kinase family, have been detected in various cancers
[1]. ALK rearrangements create an oncogenic ALK tyrosine
kinase that activates many downstream signaling pathways
resulting in increased cell proliferation and survival [1]. In
non-small cell lung carcinoma (NSCLC), the most common
ALK rearrangement is a fusion ofALK gene and echinoderm
microtubule-associated protein-like 4 (EML4) gene, formed
as a result of a small inversion within the short arm of
chromosome 2, where the genes are located [2]. EML4-
ALK fusion protein serves as a therapeutic target for an
ALK tyrosine kinase inhibitor, which has showed promising
results when used in treating NSCLC patients carrying ALK
rearrangement [3–6]. In addition to EML4, otherALK fusion
partners have also been reported in lung cancer, including
TFG [7], KIF5B [8], and KLC1 [9].
ALK gene rearrangements can be screened by various
methods, including commonly used �uorescence in situ
hybridization (FISH), immunohistochemistry (IHC), and
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real-time reverse transcription-PCR (RT-PCR). Further-
more, next-generation sequencing technology holds a great
potential as a new tool for cancer diagnostics [10]. Each of
these methods has their own advantages and disadvantages.
Hence, the optimal method to detect ALK fusions in NSCLC
remains to be determined.
In this study, we screened ALK gene fusion status by
FISH, IHC, real-time RT-PCR and targeted resequencing.
Our aim was to compare the results obtained from these
four methods in order to see how well they correlate with
each other. We especially wanted to �nd out how well FISH,
IHC, and real-time RT-PCR support the sequencing results.
Moreover, we aimed to prove the suitability of targeted rese-
quencing for testing of formalin-�xed paraﬃn-embedded
(FFPE) tumor material. To our knowledge, this is the �rst
paper comparing these four methods as means of ALK gene
fusion identi�cation.
2. Materials andMethods
2.1. Patients. Archived formalin-�xed paraﬃn-embedded
tumor specimens were collected from 87 non-small cell
lung carcinoma patients operated during 2005–2011 at the
Hospital District of Helsinki and Uusimaa (HUS), Finland.
Based on the WHO 2004 classi�cation, 80 of the patients
were diagnosed with adenocarcinoma, four with large cell
carcinoma, one with squamous cell carcinoma, and two
with unclassi�ed NSCLC. Selection of the patients for the
analyses was not random. e selected patients were mainly
nonsmokers and those with adenocarcinomas. e EGFR
gene mutation status was previously assessed for 57 patients,
of which 9 carried EGFR mutation. e mean age of the
patients was 63.7 years, ranging from 44 to 82 years. About
half of the patients were male (𝑁𝑁 𝑁 𝑁𝑁) and half were female
(𝑁𝑁 𝑁 𝑁𝑁). e tumor tissue percentage of the specimens was
con�rmed by a pathologist to be >20%.
For ALK fusion testing, we applied dual-color, break-
apart FISH, real-time RT-PCR, immunohistochemistry, and
targeted resequencing. Interpretation of the results was done
in double-blindmanner without knowing the results by other
methods.
2.2. Fluorescence In Situ Hybridization. We performed �uo-
rescence in situ hybridization on 95 FFPE tumor specimens
from 87 patients (two separate samples from 8 of the
patients), for which the tumor tissue sections (2.5 𝜇𝜇m) were
�xed on microscope slides. Deparaﬃnization of the sections,
slide pretreatment, protease pretreatment, hybridization with
Vysis LSI ALK Dual Color Break Apart FISH probes, slide
washing, and counterstaining by DAPI were done following
the manufacturer’s protocol (Abbott Molecular Inc., Des
Plaines, IL, USA). Paraﬃn melting and hybridization were
performed using StatSpinermoBrite Slide Processing Sys-
tem (Abbott Molecular Inc.). e results were viewed by
�uorescence microscope. For each sample, the number of
fused signals, single orange signals, and single green signals
was counted in 50 nuclei. Cells containing at least one green
and orange signal pair split apart by ≥2 signal diameters
(pair-signal type fusion), or a single orange signal without
corresponding green signal (single-signal type fusion), were
considered to contain ALK gene rearrangement (positive).
Fused or adjacent green and orange signals, or a single green
signal (deletion of the corresponding orange signal), were an
indication of a negative cell. Samples with ≥15% of positive
cells were considered positive.
2.3. Immunohistochemistry. Immunohistochemical stainings
were done to 14 specimens from 14 patients using mouse
monoclonal ALK antibody (clone 5A4, Novocastra, Newcas-
tle, UK), 1 : 100 with OptiView DAB detection Kit (Ventana,
Tucson, Arizona, USA), and CC1 buﬀer in BenchMark XT
(Ventana, Tucson, Arizona, USA). Due to long permission
procedures, ALK immunostaining was performed only for
FISH positive and some negative cases.
2.4. Real-TimeRT-PCR. Weevaluated 95 FFPE tumour speci-
mens from87 patients for the presence of anEML4-ALK gene
fusion using the AmoyDx EML4-ALK fusion gene detection
kit (Amoy Diagnostics, Xiamen, China). Following xylene
deparaﬃnization of a 16 𝜇𝜇M FFPE section, total RNA was
extracted using theRNeasy FFPEKit (QiagenGmbH,Hilden,
Germany) according to the manufacturer’s protocol. RNA
was quanti�ed using the Qubit �uorometric quantitation
system (Life Technologies, Carlsbad, CA, USA). 100–500 ng
of the extracted RNA was used for reverse transcription and
real-time PCR in each of the four reactions of the EML4-ALK
fusion gene detection kit according to the manufacturer’s
protocol. Reaction 1 ampli�es EML4-ALK variants 1, 2, 3a,
and 3b, reaction 2 EML4-ALK variants 4 & 4′, reaction 3
EML4-ALK variants 5a, 5b, 5′, and 8, and reaction 4 the
reference gene beta-actin. All assays were performed on
an ABI7500 instrument (Applied Biosystems, Foster City,
USA). Assay reactions achieving Ct values of ≤30 cycles were
considered positive for one of the variants detected by that
reaction mixture.
2.5. Next-Generation Sequencing
2.5.1. DNA Isolation. DNA was isolated from FFPE NSCLC
tissue specimens using QIAamp DNA Mini Kit (Qiagen
GmbH, Hilden, Germany). e isolation was performed
according to the manufacturer’s instructions for genomic
DNA puri�cation from paraﬃn-embedded tissue material
with following modi�cations: xylene was added twice and
100% ethanol was added three times for careful paraﬃn
removal, samples were incubated at 90∘C for 1 h aer
overnight cell lysis, Buﬀer AL was added normally but an
incubation at 70∘C for 10min was not performed, and in the
last step of the protocol, QIAamp Mini spin column loaded
with water was incubated at room temperature for 5min
before �rst centrifugation, and at 50∘C for 5min before the
�nal centrifugation to increase the DNA yield. DNA was
eluted in 50 𝜇𝜇L of puri�ed water. DNA concentration was
measured by Qubit �uorometer (Life Technologies).
2.5.2. Target Capture. We selected 192 genes associated with
lung cancer for target enrichment. Baits were designed to
capture all exons, 3′UTR, and 5′UTR regions of all genes,
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including ALK and EML4 genes. Additional baits were
designed from intronic region between exons 19 and 20 of
ALK gene to capture all breakpoint variants of ALK fusion
gene. Baits were designed with e-array (Agilent Technologies,
Inc., Santa Clara, CA, USA) and RNA baits obtained from
Agilent. A total of around 1MB region, including 2676 target
regions, was captured.
2.5.3. Targeted Sequencing. 2-3𝜇𝜇g of DNA, isolated from 57
formalin-�xed para�n-embedded tumor specimens from 56
patients, was fragmented, ligated to adapters, and enriched
for target regions using Agilent’s SureSelect in-solution target
capture and enrichment protocol. Paired-end sequencing
of the target-enriched libraries was performed on Illumina
HISeq2000 sequencer (Illumina, Inc., San Diego, CA, USA).
2.5.4. Primary Analysis. Data obtained from sequencing was
processed with a variant-calling pipeline (VCP) developed at
the Finnish Institute of Molecular Medicine (FIMM) [11].
Sequence reads were �ltered for quality, paired-end reads
aligned to the reference genome with the Burrows-Wheeler
Aligner (BWA) [12], and duplicate fragments removed by
rmdup algorithm. For variant calling, VCP utilized SAM-
tools’ pileup [13]. Single nucleotide variation (SNV) calling
and read end anomaly (REA) calling were based on FIMM’s
own developed algorithm. Detection of indels was performed
with the Pindel [14], and Circos [15] was used for visualiza-
tion of anomalously mapping paired-end (PE) reads. Results
were visualized in the Integrative Genomics Viewer (IGV)
[16].
For identifying ALK fusions from data, all exons and
intronic region of ALK (chr2:29,446,208-29,448,431 in build
GRCh37 of the human reference genome) were checked for
anomalously mapped paired-end reads within this region.
3. Results
FISH and real-time RT-PCR were performed on all the 87
NSCLC cases, targeted resequencing on 56 cases, and IHC on
14 cases. Successful results were obtained from all specimens
by each method. Table 1 lists all ALK-positive cases detected
by FISH, IHC, real-time RT-PCR, and targeted resequencing.
We detected ALK rearrangement by FISH in �ve patients
and one replicate sample. Two of the positive cases had pair-
signal type fusion and three of them had single-signal type
fusion. We also detected one ALK fusion-positive borderline
case with 20% of positive cells observed by �rst reader.
Aer evaluations by two other readers, it was, however,
considered negative (<15% of positive cells). No ALK fusion
was observed in this case by real-time RT-PCR, targeted
resequencing, or IHC.
Using real-time RT-PCR, we identi�ed EML4-ALK
fusion variants 1, 2, or 3a/b (without distinguishing between
them) in �ve patients and one replicate sample.
Targeted resequencing revealed four patients and one
replicate sample harboring EML4-ALK fusion (the �h
positive patient was not studied by targeted resequencing).
All positive cases by targeted resequencing had a breakpoint
in intronic region between exons 19 and 20 of ALK, and in
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F 1: A Circos plot visualizing the detection of EML4-ALK
fusion in lung cancer patient (LC14) by targeted resequencing.
intron 13 ofEML4, corresponding the fusion variant 1 in real-
time RT-PCR system. Table 1 shows detailed breakpoints of
the fusions in ALK gene.
By IHC, we detected ALK staining in �ve cases. e
results of FISH, real-time RT-PCR, targeted resequencing,
and IHC corresponded to each other, and no discrepant
results were observed. Figures 1 and 2 show a detection
of ALK fusion-positive result by targeted resequencing, and
Figure 3 represents examples of ALK fusion-positive results
detected by FISH, real-time RT-PCR, and IHC.
In total, we detected �ve (5.7%) ALK-positive cases in 87
NSCLC patients studied altogether.ree of these �ve EML4-
ALK fusion containing tumors were adenocarcinomas and
two were large cell carcinomas. Of all the studied cases, four
men and one woman carried ALK fusion, while 41 men and
41 women were considered ALK negative. All the patients
with ALK gene rearrangement were nonsmokers, and their
age ranged between 44 and 63 years (mean age = 50.4 years).
e age range amongALK fusion negative patients was 45–82
years (mean age = 64.5 years). None of the patientswithEGFR
mutation harbored ALK gene fusion. All replicate samples
of the 8 patients included in our study showed concordant
results in each method used.
4. Discussion
Non-small cell lung carcinoma patients harboring ALK gene
rearrangement have been reported to bene�t from tyrosine
kinase inhibitor treatment [3–6], which makes the reliable
screening of ALK fusions important. In addition to the com-
monly used FISH, IHC, and RT- PCR, targeted resequencing
holds great potential in the detection ofALK rearrangements.
We studied NSCLCs using FISH, IHC, real-time RT-
PCR, and targeted resequencing to detect ALK gene rear-
rangements.e results obtained from all four methods were
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F 2: Detection of EML4-ALK fusion in lung cancer patient (LC14) by targeted rese�uencing. Targeted rese�uencing identi�ed
anomalously mapped pairs on chromosome 2. e pairs map to ALK (a) and EML4 (b) in inverted orientation.
(a)
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F 3: Detection of ALK fusion in lung cancer patient (LC14) by FISH, real-time RT-PCR, and immunohistochemistry. (a) FISH
performed with Vysis LSI ALK Dual Color Break Apart FISH probes detected ALK fusion as split red and green signal. (b) An example
results graph from real-time RT-PCR showing change in the normalized reporter signal (delta Rn) against PCR cycle number for reaction 1
of the AmoyDx EML4-ALK fusion gene detection kit. (c) and (d) Immunohistochemistry revealed strong expression of ALK in ALK-fusion
positive patient (c) and no expression in ALK-fusion negative patient (d).
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interpretable andnodiscrepancies between themethodswere
observed. Table 2 shows the comparison of the methods used
for ALK fusion screening in this study.
FISH is a relatively rapid, well-standardized, rather
expensive method which only requires a small amount of
tumor biopsy. e FISH assay performed in this study is the
FDA-approved companion diagnostic for the NSCLC crizo-
tinib, which uses probes that target to ALK locus on chro-
mosome2p23, thus recognizing allALK gene rearrangements
including non-EML4-ALK fusion partners. FISH could not,
however, identify the fusion partner nor can it distinguish
between diﬀerent fusion variants. e interpretation of FISH
results is rather subjective, and a considerable variability in
interpretation of FISH results between readers have been
reported [17]. In our study, all cases were evaluated by two
experienced viewers, who read the signals for most of the
cases fast (10 to 30 minutes) and reliably. e borderline
ALK-positive case (20% of positive cells) observed by �rst
FISH reading was evaluated by two other readers, who both
detected <15% of positive cells. As the mean value of the
three analyses was less than 15% of positive cells, the sample
was considered, according to the provider of the FISH kit,
negative, underlining the relevance of reevaluation of the
borderline positive cases.e results from real-time RT-PCR,
targeted resequencing, and IHC support the interpretation,
since no ALK fusion was detected in this case by these
methods.
Immunohistochemistry is a rapid and relatively inexpen-
sive method for diagnosing ALK-rearranged NSCLCs that
require only a small biopsy sample. A great advantage of
immunohistochemistry is that tissue morphology is retained
during analysis, and thus the detection of ALK fusions can
be focused on the tumor areas. We performed immunohisto-
chemistry by usingALK antibody clone 5A4, the use of which
has showed good sensitivity in ALK fusion detection in lung
carcinomas [18–20]. In the present study, the results obtained
from IHCwere readily interpreted, and all ALK positive cases
showed a strong positive staining.
Real-time RT-PCR is a fast and sensitive method for
detection of expressed EML4-ALK gene fusions in NSCLC.
It recognizes known EML4-ALK fusion variants for which
speci�c primers have been designed, not other ALK gene
rearrangements. e real-time RT-PCR method used in this
study was able to identify 10 EML4-ALK fusion variants of
which variants 1, 2, or 3a/3b were detected. Only a small
amount of RNA (100–500 ng) was needed for the test as a
starting material. Although two samples gave only 84 ng and
90 ng of input RNA, the b-actin Ct values were considered
acceptable (a Ct value <30). All in all, the assay worked 100%
in all runs and the results were reproducible.
Targeted resequencing is a promising method for detec-
tion of ALK gene rearrangements. In the present study, the
baits for sequencing were designed to capture all break-
point variants of ALK fusion gene. We observed 73–96%
of target 20-fold coverage in our samples, which shows a
great eﬃciency of the target enrichment. All patients with
EML4-ALK fusion detected by resequencing had EML4-ALK
fusion variant 1, which is the most common variant observed
in 33% of NSCLC patients [21]. e results obtained by
targeted resequencing were interpretable and in signi�cant
correlation with results obtained by the commonly used
methods, indicating the reliability and sensitivity of targeted
resequencing in EML4-ALK gene fusion identi�cation. How-
ever, an accurate sensitivity analysis by dilution series could
not be performed using the material available for our study.
Regarding the probability of false positive results, targeted
resequencing did not detect any anomalously paired reads
from ALK region in any of 51 ALK fusion negative (FISH,
real-time RT-PCR, IHC) specimens, proving the speci�city of
targeted resequencing in ALK fusion detection. In addition
to the detection of known ALK gene fusions, targeted
resequencing holds a great advantage over other methods
by enabling the simultaneous screening of novel ALK fusion
partners as well as other lung cancer-related gene mutations,
fusions and copy number alterations, saving time and mate-
rial in the long run. In this study, we selected 192 lung cancer-
related andmiRNA genes for resequencing, although we only
focused on the ALK fusions here. Targeted resequencing also
provides a huge amount of novel information, for instance,
increasing our knowledge of resistance of some NSCLCs to
tyrosine kinase inhibitor treatment. However, the method
still faces many challenges before it is applicable to an average
laboratory of pathology. For example, expertise is needed for
analysis and interpretation of the sequencing results, as well
as means to lower the cost and speed up the turnaround time.
Furthermore, sequencing requires a relatively large amount
of DNA, which might be diﬃcult to isolate from small FFPE
biopsies. In the present study, the amount of DNA in two
analyzed specimens was less than the optimal 2-3𝜇𝜇g (1.6 𝜇𝜇g
and 1.7𝜇𝜇g, resp.) but interpretable results were obtained.
Similarly, as targeted resequencing can be used for detec-
tion of ALK gene rearrangements and other gene fusions in
lung carcinomas, it can be applied on detection of fusions in
other diseases, such as in hematologic malignancies and sar-
comas, in which multiple chromosomal translocations have
been characterized, some of them with clinical importance
[22, 23].
We detected ALK gene fusion in 5.7% of NSCLCs, which
supports previous studies reporting EML4-ALK fusion in
∼3–13% of NSCLC patients [2, 3, 24–27]. However, our
material does not present random cohort from NSCLCs,
since the samples were mainly nonsmoking patients with
adenocarcinoma. In our study, none of the patients with
EGFR mutation had an ALK gene rearrangement (data
not shown), which is in line with the literature, indicating
that EML4-ALK fusion tends to occur in adenocarcinomas
lacking EGFRmutation [17, 19, 26–29].
Formalin-�xed, paraﬃn-embedded tumor specimens are
oen the only tumor tissue material available for diagnostic
purposes. Hence, the feasibility of FFPE to the detection
methods is essential for reliable ALK fusion screening. In
this study, we showed that FFPE material is applicable for
all the four methods used for ALK gene fusion detection.
However, it is important to note the low prevalence and
limited selection of ALK gene fusions within the patient
population, which is a common issue for the development,
validation, and comparison ofALK gene fusion assays, as well
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as for the assessment of the clinical relevance of the various
ALK gene rearrangements.
5. Conclusions
Our study proved that FISH, IHC, real-timeRT-PCR, and tar-
geted resequencing can be performed successfully on FFPE
tumor specimen material. We found signi�cant concordance
among the four methods studied. Our results support the
use and further development of targeted resequencing in
detection of ALK gene fusions.
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